Status:
RECRUITING
Prognosis of Patients With Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy
Lead Sponsor:
RenJi Hospital
Collaborating Sponsors:
Shanghai Zhongshan Hospital
Tianjin Medical University Second Hospital
Conditions:
Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy
Eligibility:
All Genders
18-90 years
Brief Summary
Upper tract urothelial carcinoma (UTUC) is a rare malignant disease which accounts for 5-10% of urothelial carcinoma in the western world and 9%-30% in China. About two thirds of patients have muscle ...
Detailed Description
The patients that meet the Inclusion and Exclusion Criteria will enroll into this observational trial. The therapeutic schedule is purposed to spare the kidney of non-metastatic primary UTUC patients.
Eligibility Criteria
Inclusion
- Minimum Age: 18 Years Maximum Age: 90 Years Sex: All Gender Based: No Accepts Healthy Volunteers: No
- Criteria:
- Histopathological confirmed upper tract urothelial carcinoma;
- Refused radical nephroureterectomy, or eligible for the indications of kidney-sparing surgery;
- Participants must be willing to attend the follow-up visits;
- Sign informed consent.
Exclusion
- Unable to undergo kidney-sparing surgery;
- Life expectancy \< 6 months;
- Previous anti-tumor therapy against UTUC, including systemic chemotherapy, surgery, radiotherapy, or immunotherapy identifying by investigators.
Key Trial Info
Start Date :
November 23 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT06204406
Start Date
November 23 2023
End Date
December 31 2028
Last Update
January 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Renji Hospital
Shanghai, Shanghai Municipality, China, 200123